COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety
A Fendler, EGE de Vries… - Nature Reviews …, 2022 - nature.com
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and
associated mortality than the general population. Owing to this increased risk, patients with …
associated mortality than the general population. Owing to this increased risk, patients with …
Learning through a pandemic: the current state of knowledge on COVID-19 and cancer
The ongoing coronavirus disease 2019 (COVID-19) pandemic has left patients with current
or past history of cancer facing disparate consequences at every stage of the cancer …
or past history of cancer facing disparate consequences at every stage of the cancer …
[HTML][HTML] Antibodies against endogenous retroviruses promote lung cancer immunotherapy
B cells are frequently found in the margins of solid tumours as organized follicles in ectopic
lymphoid organs called tertiary lymphoid structures (TLS),. Although TLS have been found to …
lymphoid organs called tertiary lymphoid structures (TLS),. Although TLS have been found to …
Immune responses against SARS-CoV-2 variants after two and three doses of vaccine in B-cell malignancies: UK PROSECO study
Patients with hematological malignancies are at increased risk of severe COVID-19
outcomes due to compromised immune responses, but the insights of these studies have …
outcomes due to compromised immune responses, but the insights of these studies have …
[HTML][HTML] COVID-19: Third dose booster vaccine effectiveness against breakthrough coronavirus infection, hospitalisations and death in patients with cancer: A …
Purpose People living with cancer and haematological malignancies are at an increased
risk of hospitalisation and death following infection with acute respiratory syndrome …
risk of hospitalisation and death following infection with acute respiratory syndrome …
Breakthrough SARS-CoV-2 infections among patients with cancer following two and three doses of COVID-19 mRNA vaccines: a retrospective observational study …
Summary Background Breakthrough SARS-CoV-2 infections following vaccination against
COVID-19 are of international concern. Patients with cancer have been observed to have …
COVID-19 are of international concern. Patients with cancer have been observed to have …
Potent high-avidity neutralizing antibodies and T cell responses after COVID-19 vaccination in individuals with B cell lymphoma and multiple myeloma
A Keppler-Hafkemeyer, C Greil, PR Wratil… - Nature Cancer, 2023 - nature.com
Individuals with hematologic malignancies are at increased risk for severe coronavirus
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …
disease 2019 (COVID-19), yet profound analyses of COVID-19 vaccine-induced immunity …
[PDF][PDF] Functional immune responses against SARS-CoV-2 variants of concern after fourth COVID-19 vaccine dose or infection in patients with blood cancer
Patients with blood cancer continue to have a greater risk of inadequate immune responses
following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the …
following three COVID-19 vaccine doses and risk of severe COVID-19 disease. In the …
How I treat and prevent COVID-19 in patients with hematologic malignancies and recipients of cellular therapies
F El Chaer, JJ Auletta… - Blood, The Journal of the …, 2022 - ashpublications.org
Patients with hematologic malignancies and recipients of hematopoietic cell transplantation
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
(HCT) are more likely to experience severe coronavirus disease 2019 (COVID-19) and have …
The importance of measuring SARS-coV-2-specific T-cell responses in an ongoing pandemic
Neutralizing antibodies are considered a correlate of protection against SARS-CoV-2
infection and severe COVID-19, although they are not the only contributing factor to …
infection and severe COVID-19, although they are not the only contributing factor to …